Kornimate/medical-research-clean huggingface dataset:
evaluation of a strategy for the presentation of oral nutritional supplements in verrines for managing undernutrition in the elderly undergoing follow-up care and geriatric rehabilitation

Conditions: Patients Hospitalized in Follow up Care or Rehabilitation

Summary: protein-energy malnutrition results from an imbalance between the body's intake and needs. among the elderly in long-term care, the prevalence of undernutrition varies from 30% to 70%. it is responsible for or aggravates a state of fragility or dependence, and promotes the occurrence of morbidities. it is also associated with worsening prognosis for underlying diseases and increases the risk of death. nutritional management of undernutrition is an issue, especially in health facilities. among the various existing nutritional care methods, oral nutritional supplements should be considered in the event of failure of food enrichment measures or even at the outset in undernourished elderly people. however, compliance or acceptance of these products among the elderly remains limited and variable with consumption of oral nutritional supplements ranging between 48% and 94% according to studies, and, because of their ease of prescription, oral supplements are sometimes the only nutritional intervention.


Eligibility criteria:
inclusion criteria: * undernourished or at-risk individuals with blood albumin levels below 35 g/l or prealbumin levels below 200 mg/l, * person admitted to geriatric follow up care less than 48 hours ago, * person fed orally, * person with a prescription for an ons, * person who speaks and understands french. exclusion criteria: * person not affiliated to a national health insurance scheme * person requiring enteral or parenteral feeding * person refusing to consume ons * people at the very end of their lives
a phase 3 study of nbi-98854 for the treatment of tardive dyskinesia

Conditions: Tardive Dyskinesia

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of nbi-98854 administered once daily for the treatment of tardive dyskinesia (td) symptoms.

this is a phase 3, randomized, double-blind, placebo-controlled, parallel, fixed-dose study to evaluate the efficacy, safety, and tolerability of two doses of nbi-98854 (40 mg and 80 mg) compared to placebo, administered once daily. the study design includes a double-blind, placebo-controlled treatment period for 6 weeks and a double-blind nbi-98854 treatment period for an additional 42 weeks, for a total of 48 weeks of treatment. final follow-up assessments will be conducted 4 weeks after the last dose of the study drug.

Eligibility criteria:
inclusion criteria: 1. subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study. 2. female subjects must not be pregnant. 3. have one of the following clinical diagnoses for at least 3 months prior to screening: schizophrenia or schizoaffective disorder, or mood disorder. 4. have a clinical diagnosis of neuroleptic-induced td for at least 3 months prior to screening. 5. have moderate or severe td. 6. if using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses. 7. be in good general health. 8. have adequate hearing, vision, and language skills to perform the procedures specified in the protocol. 9. have a negative drug screen for amphetamines,barbiturates, benzodiazepines, phencyclidine, cocaine, opiates, or cannabinoids exclusion criteria: 1. have an active, clinically significant unstable medical condition within 1 month prior to screening. 2. have a known history of substance dependence, or substance (drug) or alcohol abuse 3. have a significant risk of suicidal or violent behavior. 4. have a known history of neuroleptic malignant syndrome. 5. have a known history of long qt syndrome or cardiac tachy-arrhythmia. 6. have a cancer diagnosis within 3 years of screening (some exceptions allowed) 7. have received an investigational drug within 30 days prior to screening or plan to use an investigational drug (other than nbi-98854) during the study. 8. have a blood loss ≥550 ml or donated blood within 30 days prior to baseline. 9. have an allergy, hypersensitivity, or intolerance to tetrabenazine. 10. have had previous exposure with nbi-98854 or had previously participated in an nbi-98854 clinical study. 11. are currently pregnant or breastfeeding.
abvn phase 2-studying the effect of stimulation on the auricular branch of the vagal nerve

Conditions: Gastroparesis

Summary: the purpose of this study is to find out if we can gain access to the vagus nerve which is largely an internal nerve that controls stomach function. we hope to gain access to the internal vagus nerve by electrically stimulating the nerve around the external ear. if we can do this then we hope that this will help our treatment of patients with nausea and vomiting and disordered stomach function

subjects will undergo transcutaneous stimulation of the auricular branch of the vagus nerve and also undergo blood draw before, after stimulation and later a third draw after a period of no stimulation. healthy subjects will also undergo vagal maneuver using the multi array electrodes (mea). gastroparetic subjects will also undergo vagal maneuver using either the regular ekg electrodes or the mea electrodes. subjects will also complete health history questionnaires.

Eligibility criteria:
inclusion criteria healthy volunteers * healthy volunteers with no gastric symptoms or conditions (except due to covid 19) * aged 18-80 years * willing to have electrodes placed in the external ear (abvn arm) * willing to perform vagal activity maneuver (vagal arm) * willing to have 1 tablespoon (15 ml) of blood drawn at 3 time points inclusion criteria gastroparesis subjects * gastroparesis subjects with a confirmed diagnosis of gastroparesis from a gi physician * have a formal diagnosis of gastroparesis or are seeing the gi physician for symptoms related to gastroparesis * aged 18-80 years * willing to have electrodes placed in the external ear (abvn arm) * willing to perform vagal activity maneuver (vagal arm) * willing to have 1 tablespoon (15 ml) of blood drawn at 3 time points exclusion criteria: * unable to provide consent * pregnant females * prisoners
efficacy of internet use disorder prevention

Conditions: Mental Disorders

Summary: background. the reduction of prevalence rates of internet use disorder (iud) and its effective treatment are at high priority in both public health and educational policies. school-based preventive interventions facilitate a low-threshold approach for individuals with iud, who are typically characterized by high therapy avoidance. moreover, indicated approaches which target adolescents at high-risk show larger effects than universal prevention approaches. simultaneously, they reduce unnecessary burden for the majority of high-school students that is not at-risk. the protect intervention for indicated prevention of iud in school settings was developed based on these preventive strategies. methods. three-hundred and forty adolescents, aged 12-18 years, from 40 secondary schools in germany, screened for high-risk of iud onset, will be randomly assigned to a) protect intervention group or b) assessment only control group. the tested intervention consists of a cognitive-behavioral 4-session brief-protocol. follow-up assessments are at 1, 4 and 12 months after admission. primary outcome is the 12-months incidence rate of iud. secondary outcomes are the reduction of iud and comorbid symptoms and the promotion of problem solving, cognitive restructuring and emotion regulation skills. discussion. the indicated preventive intervention protect follows the apa-guidelines for psychological prevention. it is theory- and evidence-based (guideline 1) and addresses both risk-reduction and strength-promotion (guideline 3), it considers current research and epidemiology (guideline 4) and ethical standards (guideline 5) such as professional secrecy and is designed as a systemic intervention (guideline 8) at the school-level. it is expected that the intervention decreases risk of iud onset (incidence rate).


Eligibility criteria:
inclusion criteria: * adolescents aged 12 to 18 years * written informed consent * high-risk for iud (screening: cius \>= 20) exclusion criteria: * current iud diagnosis or treatment * comorbid depression * comorbid anxiety disorder (social phobia or performance anxiety)

Keywords: internet use disorder internet gaming disorder cognitive-behavioral intervention indicated prevention adolescents internet addiction
dynamic splinting for patients with adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the purpose of this study is to compare two treatments for adhesive capsulitis.

the purpose of this study is to examine the effects of two treatment regimens for adhesive capsulitis: dynamic splinting and/or manual physical therapy.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic adhesive capsulitis * greater than 50% limitation in active flexion, internal rotation, or external rotation * tight ghj capsule in at least 2 directions * capsular end-feel primarily limits rom * age 40- 64 * normal x-rays exclusion criteria: * acute adhesive capsulitis * history of diabetes mellitus * evidence of a cuff tear * recent history of trauma * evidence of glenohumeral djd * history of shoulder surgery * calcification of tendonitis demonstrated on a current x-ray * abnormal x-ray * cervical radiculopathy/brachial plexus lesions * less than 2+/5 muscle strength during mid-line manual muscle testing * muscle atrophy * presence of associated systematic conditions * history of prior therapy for current condition * manipulation under anesthesia * non compliance * shoulder-hand syndrome, complex regional pain syndrome * history of prior injections for the current problem * patient receiving worker's compensation * shoulder symptoms with cervical provocative testing * positive x-ray findings in the acromioclavicular or sternoclavicular joints * abnormal physical signs or symptoms in the a-c or s-c joint

Keywords: adhesive capsulitis rom dynasplint
three-pronged centralized molecular analysis to optimize detection of ntrk1,2,3 fusions in thyroid cancer

Conditions: Thyroid Cancer

Summary: this multi-center study aims at ntrk fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage). the primary objective of this study is to assess the frequency of ntrk fusions in thyroid cancer. the secondary objective of this study is to develop an effective tool (testing) strategy for the detection of ntrk fusions in thyroid tumors, comparing the diagnostic tecniques available (ihc, real-time pcr and ngs).

thyroid cancer is the most common neoplasm of the endocrine system. most thyroid carcinomas originate from the follicular epithelium and are distinguished in differentiated forms (dtc): papillary (ptc) and follicular (ftc) carcinomas. both have a favorable prognosis and account for approximately 80% and 10% of all thyroid neoplasms, respectively. the undifferentiated form represented by the anaplastic thyroid carcinoma (atc) is less frequent (about 2%) and represents one of the most aggressive human tumors with a survival that rarely exceeds 6-12 months. medullary thyroid carcinoma (mtc), deriving from parafollicular c cells, is relatively rare (approximately 5%) and is associated with an intermediate prognosis between differentiated and poorly differentiated forms. as to the prevalence of ntrk lesions, many authoritative papers and reviews claim very high (up to 75%) ntrk fusion frequencies, particularly in the common ptc. however, an extensive pubmed analysis back to year 1990 does not provide convincing support for this claim.several techniques for ntrk fusion diagnosis exist, including pan-trk ihc, fish, reverse transcription pcr, dna-based next-generation sequencing (ngs), and rna-based ngs. each of these assays has unique features, advantages, and limitations, and familiarity with these assays is critical to appropriately screen for ntrk fusions. the aim of this study is to determine the frequency of ntrk fusions in advanced thyroid cancer patients and to compare the diagnostic tecniques available (ihc, real-time pcr and ngs).

Eligibility criteria:
inclusion criteria: * diagnosis of advanced thyroid cancer (any histotype) * informed consent. exclusion criteria: * patients with thyroid neoplasms without appropriate material for subsequent immunohistochemical and molecular studies; * patients with non-advanced thyroid cancer

Keywords: ntrk fusion
bioenergetic profiling and cognition in gbm patients

Conditions: Glioblastoma

Summary: this trial studies the use of blood-based bioenergetic profiling and cognitive testing in assessing patients with glioblastoma undergoing chemoradiation therapy. the purpose of this pilot research study is to find out if it is possible to see changes in participants' mitochondria, parts of a cell that produce energy, that might be associated with changes in participants' brain function after chemoradiation therapy.

primary objective: • to determine the feasibility of performing bioenergetic profiling in glioblastoma patients receiving chemoradiation by ascertaining the proportion of patients who have enough white blood cells in a 16 ml blood to successfully perform the profiling assays. secondary objectives: • to determine if either pre-radiotherapy bioenergetic profile or the change in bioenergetic profile from pre-radiotherapy to post-radiotherapy are predictive of subacute cognitive decline after radiation. outline: patients undergo neurocognitive testing over 1 hour using a customized battery of tests designed for brain tumor patients at wake forest baptist comprehensive cancer center. patients also undergo blood collection at baseline and at 1 and 3 months post radiotherapy.

Eligibility criteria:
inclusion criteria: • glioma patients greater than 18 years old receiving chemoradiation with a karnofsky performance status greater than or equal to 50. exclusion criteria: * prior diagnosis (by a physician or neuropsychologist) of any type of dementia (ad, frontotemporal dementia, vascular dementia, lewy-body dementia, parkinson's dementia), normal pressure hydrocephalus, creutzfeldt jacob disease, posterior cortical atrophy, huntington's disease, or korsakoff syndrome will be excluded. patients who were diagnosed with mild cognitive (mci) impairment greater than or equal to 1 year prior to diagnosis with their high grade glioma will also be excluded. patients reported by family members as having memory problems or with subjective memory complaints are still eligible. * patients taking medications known to have a mitotoxic effect (see attached appendix). patients who take any of the as needed medications on the list more than 4 times per week will be excluded. there are medications that are considered mitotoxic that are not included on this list because of the essential nature of the medications to this population (steroids, anti-seizure medications, diabetic medications etc.) or high frequency of use in this population (statins, beta blockers). * patients on medications with the potential to enhance cognition including donepezil, memantine, armodafinil or methylphenidate. * patients who are not fluent in english will be excluded. * patients with aphasia or other neurologic deficit which would prevent participating in cognitive testing will be excluded. * patients who are unable to fast for 8 hours will be excluded since enrolled patients will only be able to drink water for the 8 hours before blood draws. * patients who drink more than 14 alcoholic drinks per week. * patients who are active smokers.
clinical trial of thoracoscopic bullectomy surgery under spontaneous ventilating anesthesia

Conditions: Stability During Surgical Operation; Complication, Postoperative; Postoperative Hospitalization Time

Summary: with the development of video-assisted thoracoscopic surgery (vats) techniques and technology for anesthesia control, non-intubated anesthesia with spontaneous ventilation has been widely applied in vats. a multicenter randomized parallel controlled study was applied in this study to assess the efficacy and safety of thoracoscopic bullectomy surgery under intravenous anesthesia with spontaneous ventilation versus tracheal intubation general anesthesia.

intubated anesthesia with single lung mechanical ventilation (iaslv) is considered the standard of care in vats. however, this type of anesthesia has been associated with several adverse effects, which can trigger complications and increase the overall surgical risk. in order to avoid intubated-anesthesia-related adverse effects, nonintubated strategies have been proposed in recent years.encouraged by the satisfactory results with a preliminary experience of nonintubated vats, the multicenter randomized parallel controlled study is established to comparatively analyze the outcome of patients undergoing either nonintubated intravenous anesthesia with spontaneous ventilation (niiasv) or iaslv vats thoracoscopic bullectomy surgery，especially in complication rate, safety during operation, muscle recovery after surgery, the difference the postoperative hospitalization time.

Eligibility criteria:
inclusion criteria: * volunteering to participate in clinical trials and having the ability of responsibility can be signed informed consent. * 16-50 years old * preoperative chest ct diagnosed with "localized lung bulla" and needing surgical treatment * eastern cooperative oncology group(ecog) score standard ≤ 1 * asa（american society of anesthesiologists score） ≤ 2 * heart ejection fraction( ef)≥ 50% exclusion criteria: * refusing to participate in clinical trials * a history of tuberculosis or other diseases could cause pleural adhesion or more pleural effusion * bmi ≥ 25 kg/m\^2 * other not suitable situations
the impact of lifestyle behavior on in vitro fertilization (ivf) outcome

Conditions: Infertility

Summary: the purpose of this study is to prospectively examine the impact of various lifestyle habits in both men and women on the outcome of in vitro fertilization. there are 25 infertility centers in the united states which use the electronic medical record collection entity eivf, made by practice highway, to collect medical and demographic information on the patients who are undergoing treatment at these centers. information on every aspect of each cycle is also electronically collected daily during each cycle. demographic and lifestyle information will be collected on all patients prior to cycle start and lifestyle habit information will be collected each time a patient logs onto the patient portal, which averages every few days.


Eligibility criteria:
inclusion criteria: eligible patients include, any patient whose: * infertility clinic uses eivf * is scheduled to undergo an ivf cycle * has access to the internet on a daily basis * can read and understand english * logs onto the patient portal on eivf

Keywords: ivf lifestyle habits
frailty, physical capacity and lung function in postoperative cardiac surgery patients

Conditions: Cardiac Infarct; Cardiac Valve Disease; Fragility; Physical Disability

Summary: the goal of this observational and prospective study is to investigate changes in physical performance, lung function, and respiratory and peripheral muscle strength in patients during the postoperative period following coronary artery bypass grafting (cabg) and valve replacement surgery..

this study aims to investigate the physical changes in patients undergoing myocardial revascularization surgery and valve replacement. it will observe alterations in physical performance, lung function, and muscle strength during the postoperative period. the study, observational and prospective, will include individuals aged ≥18 scheduled for these surgeries, evaluating them preoperatively, post-intensive care unit discharge, and before hospital discharge. assessments involve tests like the short physical performance battery, 1-minute sit-to-stand test, clinical frailty scale, manovacuometry, dynamometry, and spirometry to identify frailty and measure muscle and lung function. the study also aims to explore predictive variables for functional loss and mortality during hospitalization.

Eligibility criteria:
inclusion criteria * age ≥ 18 years * both genders * elective coronary artery bypass grafting surgery * elective heart valve surgery * absence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the preoperative period. exclusion criteria: * surgeries performed via lateral thoracotomy or minithoracotomy * reoperation for any reason * presence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the postoperative period.

Keywords: cardiac surgery short physical performance battery 1-minute sit-tostand test spirometry muscular strength
a study to assess adverse events and effectiveness of intravenous infusions of abbv-cls-628 in adult participants with autosomal dominant polycystic kidney disease (adpkd)

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: autosomal dominant polycystic kidney disease (adpkd) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. the purpose of this study is to assess the safety and efficacy of abbv-cls-628 for the treatment of adpkd in adult participants. abbv-cls-628 is an investigational drug being developed for the treatment of adpkd. participants are placed in 1 of 4 groups, called treatment arms. each group receives a different treatment. there is a 1 in 4 chance that participants will be assigned to placebo. around 240 adult participants with adpkd will be enrolled at approximately 100 sites worldwide. participants will receive intravenous abbv-cls-628 or placebo every 4 weeks for 92 weeks. participants will be followed for up to 15 weeks. there may be higher treatment burden for participants in this trial compared to their standard of care . participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * autosomal dominant polycystic kidney disease (adpkd) class 1c, 1d, or 1e based on the mayo clinic imaging classification of adpkd. * estimated glomerular filtration rate (egfr) \>= 30 ml/min/1.73 m\^2 and \< 90 ml/min/1.73 m\^2, using the chronic kidney disease epidemiology collaboration (ckd-epi) equation at screening. exclusion criteria: * current interventions to treat adpkd such as non-approved medications or lifestyle modifications. * any exclusionary medical diseases, disorders, or conditions as described in the protocol.

Keywords: autosomal dominant polycystic kidney disease (adpkd) abbv-cls-628